



What makes a country attractive for clinical research?


Anne Sinke, PhD

Sr. Director, Medical Affairs
Belgium, the Netherlands,
Luxembourg






Approval is a milestone. Access for patients is the outcome, and it differs by country




4. Buijsman T. et al. Accessibility and Time to Reimbursement of Treatments With Substantial Benefit: A Comparative Analysis Focused on Inequalities Between Different European Countries and Different Tumor Types. Presented at ISPOR Europe 2025; Glasgow, Scotland. Available at: <https://www.ispor.org/conferences-education/conferences/upcoming-conferences/isor-europe-2025/program/program/paper/isor-europe-2025/poster-session-1-2/accessibility-and-time-to-reimbursement-of-treatments-with-substantial-benefit-a-comparative-analysis-focused-on-inequalities-between-different-european-countries-and-different-tumor-types>.

To discover, develop and deliver innovative therapeutics for life-threatening diseases




The global clinical trial ecosystem: Europe's share in pre-clinical and early phase research is declining²



2. Kang S, Ji Y. Geographic Shifts in Early-Stage Biopharmaceutical Innovation. JAMA. 2026;335(15):1355-1357. doi:10.1001/jama.2026.1962




The global clinical trial ecosystem: Europe's share in trial starts & attractiveness is declining¹



Access to & rewarding innovation is driving investments such as early research & clinical trials

Access funds tomorrow's research — globally.

Does *our* access affect whether we are chosen?



Three things we already observe in the clinic / daily practice

**Post-trial
Access**

**Ethical
Question**

**Diverging
Standard of
Care**



Likelihood of attracting industry-sponsored research depends on both axes



The Dutch opportunity: connect the strengths

Protect

Academic depth/expertise/networks, early-phase quality, strong investigators, data and registry tradition, integrity of research.

Together


Researchers, UMCs, regulators, HTA, payers, patients and industry - involved earlier and together.

Value innovation

Rewards innovation & show contribution beyond recruitment speed: science/expertise and improved & predictable implementation.

Learn

Treat trial data and real-world data as one national learning capability.



The question is not “how do we run studies faster?” but “how do we build the strongest innovation ecosystem in Europe?”

THANK YOU

